CURIS INC

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed/refractory primary central nervous system lymphoma. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreements with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed three programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.

Curis, Inc.는 미국에서 인체 암 치료를 위한 신약 후보 물질 발굴 및 개발에 주력하는 생명공학 기업입니다. 임상 단계의 신약 후보 물질로는 재발성/불응성 원발성 중추신경계 림프종 환자를 대상으로 1/2상 공개 라벨 단일군 확장 임상 시험이 진행 중인 경구용 저분자 IRAK4 키나아제 억제제 Emavusertib가 있습니다. 회사의 파이프라인에는 재발성 또는 불응성 미만성 거대 B세포 림프종 환자 치료를 위한 HDAC 및 PI3K 효소의 경구용 이중 억제제 Fimepinostat; PD-